AB 224050Alternative Names: ABR 224050
Latest Information Update: 27 Jun 2014
At a glance
- Originator Active Biotech
- Developer Lundbeck A/S
- Class Antirheumatics
- Mechanism of Action Dihydroorotate dehydrogenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Rheumatoid arthritis